Medicine · Français

Will Kodiak Sciences announce topline results from the PEAK trial of KSI-101 in macular edema secondary to inflammation by December 31, 2026?

deadline 2026-12-31 confidence medium tier 4 evidence
64%Asturna estimate
⚠ Evidence cap applied: the model proposed 65%, brought back to 64% for lack of sources solid enough to justify the departure from the base rate.

Resolution criterion

Yes if, no later than December 31, 2026, Kodiak Sciences publicly reports the topline results of the PEAK trial of KSI-101 (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("December 2026"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.

Verified starting state

As of October 28, 2026: according to the Kodiak Sciences filing of September 28, 2026, the company expects topline results in the period "December 2026". Source: https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm

What pushes it up

What pushes it down

What would move this number most

Whether the trial data will be finalized and approved for public release by the end of December 2026

How this number is built

Deadline2026-12-31
Base rate55%
Best evidencetier 4 · 2 article(s) used
Independent runs63 · 65 (spread 2 pts)
Confidencemedium
Evidence capapplied: 65% brought back to 64%
Last revised2026-10-28 15:07
Modelopenai/gpt-oss-120b (Groq)

Sources consulted

Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026tier 4 · TradingView · 2026-08-13Kodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammationtier 4 · Stock Titan · 2026-08-06